Linda A Bradley

Summary

Affiliation: Women and Infants Hospital
Country: USA

Publications

  1. doi request reprint Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer
    Linda A Bradley
    Department of Pathology and Laboratory Medicine, Women and Infants Hospital Alpert Medical School of Brown University, Providence, Rhode Island, USA
    J Urol 190:389-98. 2013
  2. doi request reprint Can Factor V Leiden and prothrombin G20210A testing in women with recurrent pregnancy loss result in improved pregnancy outcomes?: Results from a targeted evidence-based review
    Linda A Bradley
    Division of Medical Screening and Special Testing, Department of Pathology and Laboratory Medicine, Women and Infants Hospital of Rhode Island, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
    Genet Med 14:39-50. 2012

Collaborators

Detail Information

Publications2

  1. doi request reprint Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer
    Linda A Bradley
    Department of Pathology and Laboratory Medicine, Women and Infants Hospital Alpert Medical School of Brown University, Providence, Rhode Island, USA
    J Urol 190:389-98. 2013
    ..We compared the effectiveness of PCA3 (prostate cancer antigen 3) and select comparators for improving initial or repeat biopsy decision making in men at risk for prostate cancer, or treatment choices in men with prostate cancer...
  2. doi request reprint Can Factor V Leiden and prothrombin G20210A testing in women with recurrent pregnancy loss result in improved pregnancy outcomes?: Results from a targeted evidence-based review
    Linda A Bradley
    Division of Medical Screening and Special Testing, Department of Pathology and Laboratory Medicine, Women and Infants Hospital of Rhode Island, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
    Genet Med 14:39-50. 2012
    ..The certainty of evidence is moderate (high, moderate, and low) that anticoagulation of women with recurrent pregnancy loss and F5/F2 variants would currently lead to net harms...